Payment overview · 2025
General Payments
$257.26
14 reported records · 8 companies
Healthcare provider profile · identity verified
Nicole Shaw, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CULLMAN, AL · NPI 1285079020
Verified facts
What the public records show
CMS Open Payments records show Nicole Shaw, M.D. received $257.26 in general payments during 2025 across 14 reported records.
SANOFI-AVENTIS U.S. LLC accounted for 26.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Synthroid by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 208 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $69.16 | 26.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.09 | 18.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $34.27 | 13.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $30.88 | 12.0% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.58 | 9.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.97 | 7.4% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $17.27 | 6.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.04 | 5.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $257.26 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $69.16 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $48.09 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $48.09 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $30.88 | 2 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $24.58 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
47 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
208 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 583 | 160 |
| Atorvastatin Calcium | Atorvastatin Calcium | 526 | 179 |
| Pravastatin Sodium | Pravastatin Sodium | 479 | 145 |
| Lisinopril | Lisinopril | 446 | 141 |
| Losartan Potassium | Losartan Potassium | 436 | 135 |
| Gabapentin | Gabapentin | 402 | 76 |
| Hydrochlorothiazide | Hydrochlorothiazide | 376 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 373 | 119 |
| Pantoprazole Sodium | Pantoprazole Sodium | 329 | 110 |
| Trazodone Hcl | Trazodone Hcl | 309 | 99 |
| Omeprazole | Omeprazole | 300 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 289 | 95 |
| Famotidine | Famotidine | 263 | 99 |
| Metformin Hcl Er | Metformin Hcl | 259 | 83 |
| Montelukast Sodium | Montelukast Sodium | 245 | 88 |
| Sertraline Hcl | Sertraline Hcl | 232 | 71 |
| Simvastatin | Simvastatin | 211 | 56 |
| Eliquis | Apixaban | 208 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 70 |
| Meloxicam | Meloxicam | 176 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 165 | 50 |
| Metformin Hcl | Metformin Hcl | 160 | 47 |
| Potassium Chloride | Potassium Chloride | 160 | 60 |
| Carvedilol | Carvedilol | 158 | 42 |
| Furosemide | Furosemide | 152 | 66 |
| Fluticasone Propionate | Fluticasone Propionate | 144 | 89 |
| Jardiance | Empagliflozin | 144 | 36 |
| Glimepiride | Glimepiride | 118 | 33 |
| Spironolactone | Spironolactone | 115 | 31 |
| Lovastatin | Lovastatin | 114 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 114 | 35 |
| Buspirone Hcl | Buspirone Hcl | 113 | 37 |
| Methocarbamol | Methocarbamol | 113 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 95 | 32 |
| Trulicity | Dulaglutide | 92 | 20 |
| Allopurinol | Allopurinol | 90 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 89 | 25 |
| Ozempic | Semaglutide | 87 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 86 | 33 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 84 | 21 |
| Benazepril Hcl | Benazepril Hcl | 78 | 20 |
| Bupropion Hcl Sr | Bupropion Hcl | 68 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 68 | 12 |
| Atenolol | Atenolol | 64 | 20 |
| Memantine Hcl | Memantine Hcl | 64 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 15 |
| Fenofibrate | Fenofibrate | 59 | 22 |
| Celecoxib | Celecoxib | 58 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 14 |
| Ezetimibe | Ezetimibe | 55 | 19 |
| Januvia | Sitagliptin Phosphate | 55 | 11 |
| Farxiga | Dapagliflozin Propanediol | 53 | 13 |
| Bupropion Xl | Bupropion Hcl | 52 | 23 |
| Irbesartan | Irbesartan | 52 | 11 |
| Mirtazapine | Mirtazapine | 52 | 14 |
| Tramadol Hcl | Tramadol Hcl | 52 | 11 |
| Alendronate Sodium | Alendronate Sodium | 50 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 50 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | suppressed |
| Nystatin | Nystatin | 47 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 47 | 16 |
| Synthroid | Levothyroxine Sodium | 47 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | 12 |
| Pregabalin | Pregabalin | 46 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 46 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 15 |
| Glipizide Er | Glipizide | 43 | 19 |
| Glipizide | Glipizide | 42 | 12 |
| Alprazolam | Alprazolam | 41 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 11 |
| Propranolol Hcl | Propranolol Hcl | 40 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 12 |
| Telmisartan | Telmisartan | 39 | 11 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Naproxen | Naproxen | 38 | 18 |
| Valsartan | Valsartan | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 35 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 30 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | 11 |
| Valacyclovir | Valacyclovir Hcl | 29 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 27 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 21 | suppressed |
| Gemtesa | Vibegron | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 12 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Humalog | Insulin Lispro | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Cefdinir | Cefdinir | 18 | 17 |
| Ramipril | Ramipril | 18 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 13 |
| Prednisone | Prednisone | 16 | 13 |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Sutab | Sod Sulf/Pot Chloride/Mag Sulf | 16 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 15 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Nateglinide | Nateglinide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $257.26 · 14 records | SANOFI-AVENTIS U.S. LLC | ABRYSVO, Arikayce, COMIRNATY, Kerendia, Leqembi, QULIPTA, RECORLEV, TZIELD, The Cologuard Plus Collection Kit, UBRELVY | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error